脂蛋白相关磷脂酶A2在冠心病诊治方面的研究进展

doi:10.3969/j.issn.1003-9198.2023.02.021

[1] SANTOSO A, HERIANSYAH T, ROHMAN M S. Phospholipase A2 is an inflammatory predictor in cardiovascular diseases: is there any spacious room to prove the causation?[J]. Curr Cardiol Rev, 2020, 16(1): 3-10.
[2] 胡盛寿, 杨跃进, 郑哲, 等. 中国心血管病报告2018概要[J]. 中国循环杂志, 2019, 34(3): 209-220.
[3] 吴岑岑, 祖凌云, 陈少敏, 等. 急性冠状动脉综合征的发病机制及治疗进展[J]. 中华脑血管病杂志:电子版, 2021, 15(1): 6.
[4] HUANG F, WANG K, SHEN J. Lipoprotein-associated phospholipase A2: the story continues[J]. Med Res Rev, 2020, 40(1): 79-134.
[5] ASANO K, OKAMOTO S, FUKUNAGA K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma[J]. Biochem Biophys Res Commun, 1999, 261(2): 511-514.
[6] STAFFORINI D M. Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2)[J]. Cardiovasc Drugs Ther, 2009, 23(1): 73-83.
[7] MAIOLINO G, BISOGNI V, ROSSITTO G, et al. Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications[J]. World J Cardiol, 2015, 7(10): 609-620.
[8] TSELEPIS A, DENTAN C, KARABINA S, et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme[J]. Arterioscler Thromb Vasc Biol, 1995, 15(10): 1764-1773.
[9] GUERRA R, ZHAO B, MOOSER V, et al. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins[J]. J Lipid Res, 1997, 38(11): 2281-2288.
[10] DENNIS E, CAO J, HSU Y, et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention[J]. Chem Rev, 2011, 111(10): 6130-6185.
[11] LI J, WANG H, TIAN J, et al. Change in lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndrome[J]. Medicine: Baltimore, 2018, 97(28): e11517.
[12] FRAS Z, TRSAN J, BANACH M. On the present and future role of Lp-PLA2 in atherosclerosis-related cardiovascular risk prediction and management[J]. Arch Med Sci, 2021, 17(4): 954-964.
[13] PACKARD C, O’REILLY D, CASLAKE M, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group[J]. N Engl J Med, 2000, 343(16): 1148-1155.
[14] EPPS K C, WILENSKY R L. Lp-PLA(2)- a novel risk factor for high-risk coronary and carotid artery disease[J]. J Intern Med, 2011, 269(1): 94-106.
[15] DE MAURI A, VIDALI M, CHIARINOTTI D, et al. Lipoprotein-associated phospholipase A2 predicts cardiovascular events in dialyzed patients[J]. J Nephrol, 2019, 32(2): 283-288.
[16] ZHANG H, GAO Y, WU D, et al. The relationship of lipoprotein-associated phospholipase A2 activity with the seriousness of coronary artery disease[J]. BMC Cardiovasc Disord, 2020, 20(1): 295.
[17] WANG R, WANG X, ZHANG E, et al. Correlation of plasma galectin-3 and plasma lipoprotein-associated phospholipase A2 with the severity and prognosis of coronary artery disease[J]. Am J Transl Res, 2021, 13(8): 8997-9004.
[18] MOUROUZIS K, SIASOS G, OIKONOMOU E, et al. Lipoprotein-associated phospholipase A2 levels, endothelial dysfunction and arterial stiffness in patients with stable coronary artery disease[J]. Lipids Health Dis, 2021, 20(1): 12.
[19] MA C, XU Z, WANG S, et al. Change of inflammatory factors in patients with acute coronary syndrome[J]. Chin Med J: Engl, 2018, 131(12): 1444-1449.
[20] LI J, ZHOU Z, NIU X, et al. Lipoprotein-associated phospholipase A2 in cardiac disease: a potential early biomarker of unstable coronary artery disease[J]. Clin Lab, 2020, 66(5). doi: 10.7754/Clin.Lab.2019.190719.
[21] YANG L, WANG H, ZHANG Y, et al. The prognostic value of lipoprotein-associated phospholipase A in the long-term care of patients with acute coronary syndrome undergoing percutaneous coronary intervention[J]. Clin Appl Thromb Hemost, 2018, 24(5): 822-827.
[22] SHENG G, ZHOU J, ZHANG C, et al. Relationship between Lp-PLA2 and in-stent restenosis after coronary stenting: a 3-year follow-up study[J]. Scott Med J, 2021, 66(4): 178-185.
[23] YIN Y, CHEN Y, XU L, et al. Relationship of lipoprotein-associated phospholipase A2(Lp-PLA2) and periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention[J]. Int J Cardiol Heart Vasc, 2020, 28: 100541.
[24] SVAROVSKAYA A, TEPLYAKOV A, GUSAKOVA A, et al. Role of markers of inflammation and endothelial dysfunction in the prognosis of the development of cardiovascular complications in patients with coronary artery disease and metabolic syndrome after coronary stenting[J]. Kardiologiia, 2020, 60(8): 98-105.
[25] SERRUYS P, GARCÍA-GARCÍA H, BUSZMAN P, et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque[J]. Circulation, 2008, 118(11): 1172-1182.
[26] WILENSKY R, SHI Y, MOHLER E, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development[J]. Nat Med, 2008, 14(10): 1059-1066.
[27] WHITE H, HELD C, STEWART R, et al. Darapladib for preventing ischemic events in stable coronary heart disease[J]. N Engl J Med, 2014, 370(18): 1702-1711.
[28] O’DONOGHUE M, BRAUNWALD E, WHITE H, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial[J]. JAMA, 2014, 312(10): 1006-1015.
[29] PRASAD M, LENNON R, BARSNESS G, et al. Chronic inhibition of lipoprotein-associated phospholipase A does not improve coronary endothelial function: a prospective, randomized-controlled trial[J]. Int J Cardiol, 2018, 253: 7-13.
[30] CHOI W, PRASAD M, LENNON R, et al. Long-term darapladib use does not affect coronary plaque composition assessed using multimodality intravascular imaging modalities: a randomized-controlled study[J]. Coron Artery Dis, 2018, 29(2): 104-113.

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 12

Metrics

Recommended 10

[1]	GU Chonghuai, XIANG Xuejun, ZHENG Yuanxi, QIAO Rui, LIN Song. Efficacy of dapagliflozin in elderly patients undergoing coronary intervention with type 2 diabetes mellitus and ejection fraction reduced heart failure [J]. Practical Geriatrics, 2024, 38(10): 1025-1029.
[2]	XU Shouyong, YUAN Yong. Study on feasibility of dual-low-dose CT coronary angiography in elderly patients [J]. Practical Geriatrics, 2024, 38(10): 1054-1058.
[3]	ZHANG Jingjing, ZHU Xiaoxia, YAO Chunlei, WANG Wei. Correlation between control nutritional status score and heart failure in elderly patients with coronary artery disease [J]. Practical Geriatrics, 2024, 38(7): 697-700.
[4]	ZHA Zhimin, LIU Huan, WANG Xiangming, LI Qiushuang, GUO Yan. Effect of cardiac valve calcification on prognosis of elderly patients with coronary heart disease [J]. Practical Geriatrics, 2024, 38(3): 245-250.
[5]	. [J]. Practical Geriatrics, 2024, 38(3): 308-311.
[6]	ZHANG Ying, XIE Ling, YE Jiaqi, QIANG Wenhui, YAN Xiaoyun, JIANG Ying, ZHANG Qing. Correlation between laminin and major adverse cardiovascular events in elderly patients with acute myocardial infarction [J]. Practical Geriatrics, 2024, 38(2): 149-151.
[7]	. [J]. Practical Geriatrics, 2023, 37(2): 109-111.
[8]	JI Jia-lin, LIU Jing, WANG Xue-li, FENG Hong-lin, HAN Xu. Ameta-analysis and sequential analysis of the effects of Guanxinping on coronary heart disease [J]. Practical Geriatrics, 2023, 37(2): 128-133.
[9]	WEI Mei, GUO Qi-feng, DUAN Li-nan, YIN Ya-juan, LIU Gang, ZHENG Ming-qi, LIU Yong-sheng. Association between subclinical hypothyroidism and death in elderly patients after percutaneous coronary intervention [J]. Practical Geriatrics, 2023, 37(2): 138-141.
[10]	YAO Jun-xiu, GUO Jin-chun, HAO Xiao-dan, LI Long-xin, YANG Xue, WANG Zhang. Expression and diagnostic value of hepatocyte growth factor in patients with chronic coronary syndrome [J]. Practical Geriatrics, 2023, 37(2): 173-177.
[11]	WU Zi-Qiang, DING Li, JIANG Ya-Wen, XIE Zhi-Quan, WANG Ji-Ye, ZHOU Pei-Yi, WANG Li-Li. Influence of exercise training on exercise tolerance in aged patients with stable angina pectoris [J]. Practical Geriatrics, 2010, 24(2): 153-155.
[12]	CHEN Jian-Hui, CHEN Long-Dian, LI Qin, XU Xin-Xin. [J]. Practical Geriatrics, 2010, 24(2): 174-175.